Stage III Cutaneous Melanoma AJCC v7 Recruiting Phase 2 / 3 Trials for Sargramostim (DB00020)

Indication	Status	Phase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)	Recruiting	2 / 3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02339571	A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	Treatment	Ipilimumab (DB06186) Nivolumab (DB09035) Sargramostim (DB00020)